|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Extracellular domain of recombinant human c-erbB-2/HER-2 oncoprotein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunoprecipitation (IP)||2µg/mg protein lysate|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13679 targets HER-2 in immunoprecipitation applications and shows reactivity with Human samples.
The MA5-13679 immunogen is extracellular domain of recombinant human c-erbB-2/HER-2 oncoprotein.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
IP-MS enrichment of ERBB2 (LFQ intensity): ERBB2 was enriched 271-fold from HCT116 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and ERBB2 antibody (Part No. MA5-13679). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
BCL6 positively regulates AID and germinal center gene expression via repression of miR-155.
MA5-13679 was used in immunohistochemistry to study the role of miR-155 repression in the mechanism by which BCL6 regulates the expression of AID and germinal centre genes
|Basso K,Schneider C,Shen Q,Holmes AB,Setty M,Leslie C,Dalla-Favera R||The Journal of experimental medicine (209:2455)||2012|
Lymphoepithelioma-like carcinoma of the ovary.
MA5-13679 was used in immunohistochemistry to report on a case of lymphoepithelioma-like carcinoma of the ovary
|Ambrosio MR,Rocca BJ,Onorati M,Mourmouras V,Mastrogiulio MG,Crispino S,Liberatore C,Santopietro R||International journal of surgical pathology (19:514)||2011|
Identification of a morphometrical parameter that predicts the response to splenectomy in patients with idiopathic thrombocytopenic purpura.
MA5-13679 was used in immunohistochemistry to study mean maximun follicle diameter as a parameter for predicting the outcome of splenectomy in idiopathic thrombocytopenic purpura patients
|Bakkaloglu H,Dinccag A,Yanar H,Tunca F,Dogan O,Cermik H,Kucukkaya R||The Tohoku journal of experimental medicine (210:49)||2006|
Association between growth factor heregulin1¿ and receptors in growth of ovarian cancer cell line with high potentiality of peritoneal dissemination.
MA5-13679 was used in immunocytochemistry to study the expression of heregulin-1alpha and it receptors and their association with the growth of an ovarian cancer cell line with high peritoneal dissemination capacity
|Nishiyama H,Soeda S,Watanabe T,Fujimori K||Fukushima journal of medical science (58:22)||2012|
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
MA5-13679 was used in blocking or activating experiment to develop and evaluate a multi-epitope vaccine targeting HER-2
|Dakappagari NK,Pyles J,Parihar R,Carson WE,Young DC,Kaumaya PT||Journal of immunology (Baltimore, Md. : 1950) (170:4242)||2003|